Immuneering Corporation
$5.53
▲
2.25%
2026-04-21 07:29:01
immuneering.com
NGM: IMRX
Explore Immuneering Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$359.47 M
Current Price
$5.53
52W High / Low
$10.08 / $1.1
Stock P/E
—
Book Value
$3.38
Dividend Yield
—
ROCE
-26.76%
ROE
-43.12%
Face Value
—
EPS
$-1.27
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
53
Beta
0.43
Debt / Equity
1.75
Current Ratio
17.5
Quick Ratio
17.5
Forward P/E
-4.08
Price / Sales
—
Enterprise Value
$187.88 M
EV / EBITDA
-3.18
EV / Revenue
—
Rating
Strong Buy
Target Price
$17
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Quantum BioPharma Ltd. | $3.12 | — | $25.24 M | — | -300.19% | -3.47% | $52 / $2.85 | $1.81 |
| 2. | CytomX Therapeutics, Inc. | $4.89 | — | $1.06 B | — | -21.31% | -35.25% | $8.21 / $0.61 | $0.58 |
| 3. | RenovoRx, Inc. | $1 | — | $45.05 M | — | -176.68% | -2.26% | $1.45 / $0.7 | $0.15 |
| 4. | Minerva Neurosciences, Inc. | $6.89 | — | $289.51 M | — | -15.79% | 352.58% | $12.46 / $1.3 | $-3.25 |
| 5. | Puma Biotechnology, Inc. | $7.37 | 12.05 | $374.96 M | — | 27.62% | 27.97% | $7.9 / $2.75 | $2.59 |
| 6. | Evaxion A/S | $4.49 | — | $37.11 M | — | -38.23% | -1% | $12.15 / $1.25 | $2.04 |
| 7. | Immunome, Inc. | $24.25 | — | $2.79 B | — | -35.12% | -52.09% | $27.65 / $6.96 | $5.61 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -13.75 M | -15.38 M | -14.76 M | -15.49 M | -18.56 M | — |
| Net Profit | -11.58 M | -14.96 M | -14.43 M | -15.05 M | -18.05 M | — |
| EPS in Rs | -0.18 | -0.23 | -0.22 | -0.23 | -0.28 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0.32 M |
| Operating Profit | -59.38 M | -64.07 M | -58.41 M | -51.75 M |
| Net Profit | -56.02 M | -61.04 M | -53.47 M | -50.51 M |
| EPS in Rs | -0.87 | -0.94 | -0.83 | -0.78 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 231.99 M | 52.71 M | 102.58 M | 122.37 M |
| Total Liabilities | 13.5 M | 11.33 M | 12.01 M | 12.52 M |
| Equity | 218.48 M | 41.39 M | 90.58 M | 109.85 M |
| Current Assets | 176.25 M | 39.59 M | 89.08 M | 108.75 M |
| Current Liabilities | 10.07 M | 7.5 M | 7.85 M | 8.05 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -45.34 M | -55 M | -48.97 M | -44.1 M |
| Investing CF | -88.74 M | 26.43 M | 7.3 M | 41.83 M |
| Financing CF | 226.58 M | 5.3 M | 28.44 M | 0.02 M |
| Free CF | -45.49 M | -55.08 M | -49.31 M | -44.84 M |
| Capex | -0.14 M | -0.08 M | -0.34 M | -0.74 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -14.15% | -5.86% | — | — |
| Profit Margin % | — | — | -15937.29% | — |
| Operating Margin % | — | — | -16325.92% | — |
| Gross Margin % | — | — | 50.11% | — |
| EBITDA Margin % | — | — | -16238.45% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.